The Valley Desk

NCT01356849 · Interventional trial

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

Overall registry status Completed

Phase 2

Conditions Chronic Kidney Disease, Diabetic Nephropathy

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov